Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study

Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have had an inadequate response to standard therapies.

The study achieved its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks compared to placebo.

In the Phase 3b APEX study, Tremfya-treated patients also exhibited significantly less progression of structural damage versus patients receiving a placebo at Week 24 as assessed by the PsA modified van der Heijde-Sharp (vdH-S) score, which includes joint space narrowing and erosion subscores.

Also Read: US Judge Rejects Another Johnson & Johnson Attempt To Use Bankruptcy ...